Cite
HARVARD Citation
Nissen, S. et al. (2016). Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial. Clinical cardiology. 39 (3), pp. 137-144. [Online].